1-5 of 5
Hans K. Erickson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Calicheamicin Antibody–Drug Conjugates with Improved Properties

Available to Purchase
Breanna S. Vollmar, Chris Frantz, Melissa M. Schutten, Fiona Zhong, Geoffrey del Rosario, Mary Ann T. Go, Shang-Fan Yu, Douglas D. Leipold, Amrita V. Kamath, Carl Ng, Keyang Xu, Josefa dela Cruz-Chuh, Katherine R. Kozak, Jinhua Chen, Zijin Xu, John Wai, Pragya Adhikari, Hans K. Erickson, Peter S. Dragovich, Andrew G. Polson, Thomas H. Pillow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 1112–1120.
https://doi.org/10.1158/1535-7163.MCT-20-0035
Published: 01 June 2021
View article titled, Calicheamicin Antibody–Drug Conjugates with Improved Properties
Open the PDF for Calicheamicin Antibody–Drug Conjugates with Improved Properties in another window
Includes: Supplementary data
Journal Articles

A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Free
Rajeeva Singh, Yulius Y. Setiady, Jose Ponte, Yelena V. Kovtun, Katharine C. Lai, E. Erica Hong, Nathan Fishkin, Ling Dong, Gregory E. Jones, Jennifer A. Coccia, Leanne Lanieri, Karen Veale, Juliet A. Costoplus, Anna Skaletskaya, Rabih Gabriel, Paulin Salomon, Rui Wu, Qifeng Qiu, Hans K. Erickson, John M. Lambert, Ravi V.J. Chari, Wayne C. Widdison
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1311–1320.
https://doi.org/10.1158/1535-7163.MCT-16-0021
Published: 02 June 2016
View article titled, A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Open the PDF for A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells in another window
Includes: Supplementary data
Journal Articles

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

Free
Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold, Carmela A. Provenzano, Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audette, Manish Gupta, Jan Pinkas, Jay Tibbitts
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (5): 1133–1142.
https://doi.org/10.1158/1535-7163.MCT-11-0727
Published: 08 May 2012
View article titled, The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Open the PDF for The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates in another window
Includes: Supplementary data
Journal Articles

Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.

Free
Katharine C. Lai, Hans K. Erickson, Xiuxia Sun, Peter U. Park, Jutta Deckert, Min Li, Yong Yi, Jan Pinkas, Jennifer A. Coccia, Sara Nadworny
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B209.
https://doi.org/10.1158/1535-7163.TARG-11-B209
Published: 12 November 2011
View article titled, Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.
Journal Articles

Abstract C61: Factors determining sensitivity of tumor cells to lorvotuzumab mertansine in vitro.

Free
Olga Ab, Victor S. Goldmacher, Laura M. Bartle, Xiuxia Sun, Hans K. Erickson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C61.
https://doi.org/10.1158/1535-7163.TARG-11-C61
Published: 12 November 2011
View article titled, Abstract C61: Factors determining sensitivity of tumor cells to lorvotuzumab mertansine in vitro.